{"Clinical Trial ID": "NCT00082641", "Intervention": ["INTERVENTION 1:", "Bras I", "Patients are vaccinated with p53-infected autologous dendritic cells subcutaneously (SC) 1 week after completion of doxorubicin and cyclophosphamide, 1 week after completion of paclitaxel (or after surgery in patients with stage III disease) and 6 and 12 weeks after completion of radiotherapy (for a total of 4 vaccinations).", "\u2022 Dendritic autologous dendritic vaccine adenovirus p53: administered subcutaneously on one of the two regimens", "INTERVENTION 2:", "Army II", "Patients receive vaccination with autologous dendritic cells infected with p53 to 6, 8, 10 and 12 weeks after the end of radiotherapy.", "\u2022 Dendritic autologous dendritic vaccine adenovirus p53: administered subcutaneously on one of the two regimens"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "Invasive breast cancer confirmed histologically meets the following criteria:", "A clinically advanced disease (stage III) with a primary tumour of at least 4 cm by mammography, ultrasound or palpation AND/or palpable axillary lymph nodes of more than 1 cm", "\u2022 Anticipated neoadjuvant chemotherapy", "P53-overpressing tumor by immunohistochemistry", "\u2022 Delayed type hypersensitivity to at least 1 out of 3 standard antigens", "- Hormonal receptor status:", "Unspecified", "CHARACTERISTICS OF PATIENTS:", "Age", "- 19 years and over", "Gender", "Women", "Status of menopause", "Unspecified", "State of play", "ECOG 0-1", "Life expectancy", "Unspecified", "Haematopoietic", "\u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014", "Number of platelets > 100 000/mm^3", "Hepatic", "Bilirubine < 2 times the upper limit of normal (ULN)", "Negative hepatitis B surface antigen", "Antibody of hepatitis C negative", "Renal", "Creatinine < 2 times ULN", "Immunological", "Negative to HIV", "No prior or concomitant autoimmune disorder", "Other", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective contraception during and for at least 6 months after participation in the study.", "No other concomitant disease that would prevent participation in the study", "THERAPE PRIOR CONCURENT:", "Biological therapy", "Unspecified", "- Chemotherapy", "See Disease Characteristics", "No previous chemotherapy", "Endocrinotherapy", "Unspecified", "Radiotherapy", "Unspecified", "Surgery", "See Disease Characteristics", "Other", "No concurrent participation in another clinical therapeutic trial"], "Results": ["Performance measures:", "Number of participants who experienced vaccine toxicity", "This outcome measure focuses on vaccine safety by documenting the number of levels 2, 3 or toxicity to participants in relation to the vaccine.", "Time: 1 week after each dose of vaccine.", "Results 1:", "Title of the arm/group: Arm I", "- Arm/group description: Patients receive vaccination with p53-infected autologous dendritic cells (SC) 1 week after completion of doxorubicin and cyclophosphamide, 1 week after completion of paclitaxel (or after surgery for patients with stage III disease), and 6 and 12 weeks after completion of radiotherapy (for a total of 4 vaccinations).", "\u2022 Dendritic autologous dendritic vaccine adenovirus p53: administered subcutaneously on one of the two regimens", "Total number of participants analysed: 11", "Type of measure: Number of participants", "Unit of measure: Participants 0 0.0%", "Results 2:", "Title of arm/group: Arm II", "Description of the arm/group: Patients receive vaccination with autologous dendritic cells infected with p53 at 6, 8, 10 and 12 weeks after the end of radiotherapy.", "\u2022 Dendritic autologous dendritic vaccine adenovirus p53: administered subcutaneously on one of the two regimens", "Total number of participants analysed: 12", "Type of measure: Number of participants", "Unit of measure: Participants 0 0.0%"], "Adverse Events": ["Undesirable Events 1:", "Total: 5/11 (45.45 per cent)", "1/11 (9.09%)", "1/11 (9.09 per cent)", "Fever 1/11 (9.09 %)", "- Skin infection [1]1/11 (9.09%)", "- Hip fracture 0/11 (0.00 %)", "1/11 (9.09%)", "Adverse Events 2:", "Total: 1/12 (8.33 per cent)", "Nausea 0/12 (0.00 %)", "- Vomiting 0/12 (0.00 %)", "Fever 0/12 (0.00 %)", "- Skin infection [1]0/12 (0.00 %)", "1/12 (8.33%) hip fracture", "- Confusion 0/12 (0.00 %)"]}